228 related articles for article (PubMed ID: 20198455)
21. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.
Barroeta JE; Baloch ZW; Lal P; Pasha TL; Zhang PJ; LiVolsi VA
Endocr Pathol; 2006; 17(3):225-34. PubMed ID: 17308359
[TBL] [Abstract][Full Text] [Related]
23. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.
Torregrossa L; Faviana P; Filice ME; Materazzi G; Miccoli P; Vitti P; Fontanini G; Melillo RM; Santoro M; Basolo F
Thyroid; 2010 May; 20(5):495-504. PubMed ID: 20450430
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.
Volante M; Bozzalla-Cassione F; DePompa R; Saggiorato E; Bartolazzi A; Orlandi F; Papotti M
Virchows Arch; 2004 Aug; 445(2):183-8. PubMed ID: 15252732
[TBL] [Abstract][Full Text] [Related]
25. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
26. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls.
Lacoste-Collin L; d'Aure D; Bérard E; Rouquette I; Delisle MB; Courtade-Saïdi M
Cytopathology; 2014 Jun; 25(3):160-9. PubMed ID: 24460983
[TBL] [Abstract][Full Text] [Related]
27. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
28. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.
Saleh HA; Feng J; Tabassum F; Al-Zohaili O; Husain M; Giorgadze T
Cytojournal; 2009 Sep; 6():18. PubMed ID: 19826479
[TBL] [Abstract][Full Text] [Related]
30. Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1.
Nehal S; Mittal R; Misra P; Rath J; Senapati U
Ann Diagn Pathol; 2022 Jun; 58():151931. PubMed ID: 35255428
[TBL] [Abstract][Full Text] [Related]
31. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
32. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
[TBL] [Abstract][Full Text] [Related]
33. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma.
Sack MJ; Astengo-Osuna C; Lin BT; Battifora H; LiVolsi VA
Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
35. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
36. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
Bogdańska M; Górnicka B; Ziarkiewicz-Wróblewska B; Koperski L; Morton M; Wasiutyński A
Endokrynol Pol; 2006; 57(4):314-9. PubMed ID: 17006830
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Borson-Chazot F; Lifante JC; Sturm N; Lavérriere MH; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2013 Sep; 209(9):585-92. PubMed ID: 23910176
[TBL] [Abstract][Full Text] [Related]
39. Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers.
Abrosimov AY; Dvinskikh NY; Sidorin AV
Bull Exp Biol Med; 2016 Mar; 160(5):698-701. PubMed ID: 27023100
[TBL] [Abstract][Full Text] [Related]
40. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]